mrajesh7493
10+ Views

Significant Impact of COVID-19 on Absorbable Heart Stent in Healthcare Industry


Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 or 2019-nCoV, is a human infectious disease caused by the coronavirus that causes severe acute respiratory syndrome. COVID-19 was declared a pandemic by the world health organization due to the rapid rise in human infection rates. The COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of corona virus have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and a total of 2 million vaccine doses have been administered.

On March 11, 2020, the World Health Organization declared the coronavirus COVID-19 pandemic.

Coronavirus disease 2019 (COVID-19) is a worldwide pande0mic, and cardiovascular complications and arrhythmias in these patients are common. Cardiac monitoring is recommended for at-risk patients. The novel coronavirus pandemic has significantly impacted the timely delivery of surgical or stent treatment for patients with severe coronary vascular disease. This has created a large backlog of work and upstaging of disease with consequent increase in risk and cost of treatment and potential for worse long-term outcomes. As countries emerge from lockdown but with COVID-19 pandemic in society, precautions remain that restrict ‘normal’ practice.
Stents are small, expandable tubes that treat narrowed arteries. Coronary artery stents are used to open the blockage of arteries or to expand the narrowing arteries, which helps to treat a heart attack, and reduce pain like chest pain. Absorbable Heart Stents are said to be “the fourth revolution” after balloon angioplasty, baremetal stents, and drug-eluting stents. As these provide mechanical support for a determined period and then disappear from the vessel, allowing its natural healing, and avoiding the risks associated with having a permanent metallic cage, such as stent thrombosis. The absorption of the stent could potentially lead to a recovery of the endothelial function of the vessel, making it responsive again to vasoactive agents. The potential benefits, including the decreased risk of stent thrombosis at long-term follow-up, one of the most feared complications of metallic stents, have led to absorbable stents, a field of growing interest in interventional cardiology.
The increasing prevalence of geriatric population and adoption of sedentary lifestyle along with the rise of obesity in people are driving the absorbable heart stent market as coronary artery diseases require appropriate surgeries for 'their treatment’. But there is a negative impact of COVID-19 on the absorbable heart stent market due to massive disruption of supply chains, and financial fragility forced manufacturers to shut down their industries as absorbable stents require high financial inputs for manufacturing.
For Instance,
· According to the Center for Disease Control and Prevention (CDC), about 18.2 million US adults age 20 and older have CAD (about 6.7%), which has required appropriate treatment
· According to the European Cardiovascular Disease Statistics 2017, each year, cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU)
Moreover, COVID-19 has made it more challenging for the manufacturing companies to bridge the losses and attempt to fulfil the demands during these times. The COVID-19 has impacted the business of manufacturers, and other service providers that are involved in absorbable heart stent devices.

IMPACT ON PRICE

COVID-19 has forced the countries to impose lockdown and restrictions worldwide. This has affected many industries and economies. The total lockdown in various countries forbade the transportation of raw materials, and the business of service providers. So, manufacturing absorbable heart stent devices has become difficult, which directly impacted the prices largely.
For instance,
· In 2020, National Pharmaceutical Pricing Authority (NPPA) has been approved to hike the prices of absorbable heart stent on seeing the current scenario and making it easy for the manufacturers.

IMPACT IN DEMAND

The outbreak of the coronavirus has shown impacts on various markets around the world. It is the cause of lockdown and isolation, which ultimately has an impact on global economic activity. This is why the global epidemic has shrunk by 1.0% in the current year.
Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities.
As heart patients are under suspection for higher exposure to COVID-19, demand for absorbable stents surges as companies are making efforts to provide help to healthcare systems to overcome the scarcity of stents while treating CAD. Absorbable stents are in high demand due to the high prevalence of interventional cardiology and peripheral vascular procedures amid the COVID-19 pandemic, which prevents the patient from staying in the hospital for long.
The clinical observations suggest that a person with heart disease has been more prone to COVID-19, which lead to clinical complications. Therefore, the government of various countries laid guidelines for special care, and treatment for heart patients. This has surged the demand for absorbable stents among people for early treatment of CAD to prevent complications of COVID-19.
For Instance,
· According to an early bulletin released by the American College of Cardiology (ACC) on March 6, 2020, people who have underlying cardiovascular disease, have a higher mortality rate when it comes to COVID-19 (10.5 percent) than people who have an underlying chronic respiratory disease (6.3 percent)
· According to the American Journal of the Medical Sciences, the COVID-19 mortality rate for people with pre-existing cardiovascular disease was between 10.5 and nearly 14 percent, and the number surged to between 35 percent and almost 87 percent for people who had underlying coronary artery disease

IMPACT ON SUPPLY CHAIN

The COVID-19 outbreak has disrupted the supply chains for absorbable heart stents globally. The sudden outbreak of COVID-19 and its subsequent impact on restrictions on trade and development of goods has resulted in a shutdown of vast portions of the global economy, resulting in disrupted supply chains due to transportation cessation, which affected the manufacturing unit largely.
Companies in the arterial stents market are helping healthcare systems to stock inventory and medical devices in order to avoid supply shocks amidst the COVID-19 pandemic.
For instance,
· According to FDA, there have been reported shortages of medical devices and equipment amid COVID-19 due to disruption of supply and service providers
· According to Springer, 2020, many companies experienced dramatic exposure to supply chain disruptions during the pandemic and the subsequent lockdowns (Strange 2020) due to their reliance on offshore supplies

STRATEGIC INITIATIVES FOR MANUFACTURERS

A large pool of the population affected by this COVID-19 virus, and its spread is expanding across the world in the last few months. To deal with the COVID-19 outbreak challenges, many market players are creating new strategies.
The key players engaged in providing products such as Medtronic, Boston Scientific Corporation, Abbott, Cook Group, Angiomed GmbH & Co. Medizintechnik KG face challenges to keep the growth during coronavirus and to maintain the demand and supply chain with proper protection of the employees.
For instance,
· Medtronic focused on providing special protection and care to its employees. Its manufacturing and distribution facilities are routinely cleaned and sanitized, employees are utilizing personal protective equipment (PPE) and social distancing, including staggered breaks to reduce crowds in common areas, and additional screening and access protocols have been implemented.
· Medtronic increased contributions to its Employee Emergency Assistance Fund, which is providing need-based financial grants to employees who are experiencing economic impact due to the COVID-19 pandemic, including childcare reimbursement.
· Boston Scientific Corporation is providing extra precautions, including increased cleaning measures, social distancing protocols, and the use of face coverings for employees who work onsite, along with personal protective equipment (PPE) for employees in the workplace ensuring business continuity.

CONCLUSION

The COVID-19 has impacted the market positively. To summarize, the prices for this market has increased as manufacturing requires raw materials which have been disrupted amid COVID-19. The demand for absorbable heart stent market has been increasing due to the prevalence of geriatric population and adoption of sedentary lifestyle which leads to various coronary vascular diseases, but the supply chain and service providers are unable to satisfy the needs, and thus, have impacted largely. However, manufacturers, service providers, and the government are making new guidelines to work safely in the workplace in the new normal and combat the gap between demand and supply. Overall, various measures have been taken by the market players to improve their business and the quality of their services.
Comment
Suggested
Recent
Cards you may also be interested in
Real World Evidence Are Used To Monitor The Post Market Safety and Adverse Events of Drugs
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be very helpful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while helping to organize and evaluate clinical data for regulatory submissions. The uncertainty brought on by the COVID-19 pandemic has dramatically shifted how and when patients decide to seek medical care. In addition, shifts in healthcare coverage and provision during the pandemic have changed the discovery and reporting of certain outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes.   RWE is set to become the most influential emerging technology to help in the fight against the COVID-19 outbreak, according to the latest poll on GlobalData’s Pharmaceutical Technology website. In this poll, which was completed by 935 of its readers in April 2021, more than one-third of the respondents indicated that RWE would have the greatest impact on the management of COVID-19.  Even though emerging technologies, such as telemedicine, have existed for decades, most of healthcare systems rely heavily on in-person interactions between patients and clinicians. Nevertheless, the current requirement for social distancing measures is swiftly pushing the primary care provision toward remote care. Telemedicine and virtual care may also prompt a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991 The utilization of RWE in infectious disease control is not a new concept. During the Ebola outbreak in 2014, forecasters successfully used Global Epidemic and Mobility (GLEaM) simulations that combined real-world data on populations and their mobility with rigorous stochastic models of disease transmission to predict the global spread of the disease.  In countries with strict data privacy laws, the implications of contact-tracing apps on individual privacy are considered a major associated concern. While cryptographers are currently working on improving tracing apps to address the issue, tracking apps can only be effective when they are used by a significant proportion of the population. Therefore, it is critical that the functionality and safety of these applications are considered acceptable by the majority of the population.  Through the analysis of the data generated from various networks, healthcare organizations can benefit from sensible information, resulting in real-time disease monitoring and control. However, as the use of technology as a means to produce more and more data to drive insights and foresight increases, the ability to automate and analyze that data becomes a necessity. Accelerated digitalization in the healthcare space has revealed gaps in infrastructure, workforce, and digital education that ultimately need to be bridged.   Real World Evidence Solutions Market Dynamics Without intelligent analytics, RWE alone will not be able to produce meaningful and actionable results. Previously, the healthcare industry did not have the ability to gather RWE at the speed and scale needed to address urgent public health crises. However, this scenario has changed due to the pandemic. Advances in analytics and access to broad and diverse real-world data sets have made it possible to rapidly analyze data as it is captured to better understand how pandemics like COVID-19 are unfolding.  The pre-approved use of RWE in efficacy decisions is being carried out currently, and there is potential for it to be used more broadly, such as in oncology, rare diseases, and pediatric conditions when randomized controlled clinical trials are impossible or unethical to conduct. In parallel, legislators are recognizing the value of RWE. In the US, the 21st Century Cures Act, passed in December 2016, has established public-private partnerships to collect data and improve the understanding of diseases. 
India Plant Protein Market Experienced A Positive Growth In CAGR
The plant-based protein market in India has been recording a strong growth in recent quarters across segments such as dairy alternatives, supplement products, meat substitutes, and processed products. The growth is mainly driven by the rising purchasing power of lower and middle-income families, increasing demand for gluten-free and lactose-free products. It is expected that increasing number of youths going to gyms, fitness clubs, and growing health consciousness especially among GenZ and millennials is likely to drive the market growth in the short to medium term. With the growing fear of coronavirus infection, people are increasingly avoiding the consumption of animal products across the globe. The trend is also evident in the Indian market. Additionally, the contagion is also galvanizing the demand for herbal foods and beverages as an immunity booster. As a result, shifting consumers’ preference from animal products to plant-based protein during the ongoing pandemic is creating growth prospect for the Indian plant-protein market. The growing awareness of animal cruelty is another key driver for the plant-based products in India. The surge in social media videos showing cruelty inflicted on animals in meat and dairy industries is one of the reasons, millennials and Gen Z are shifting towards meatless meat products. The growing awareness and demand for innovative plant-based protein are creating opportunities for the ever-growing startup ecosystem in India. The plant protein market is still in a nascent stage in its development and therefore several startups are entering into space. To establish their presence in the Indian plant protein market, small businesses are moving faster and raising funds for product innovation and development. The growing sales of plant-based meat and dairy products in restaurants and foodservice channels are also supporting the market. With the rising demand, more retailers around the country are expected to introduce private label products in the market. Retailers like Reliance Fresh, D-Mart, and Big Bazaar are already providing shelf space to plant-based products from different brands including Chetran Foods. The plant protein market in India has recorded a strong growth with a CAGR of 36.1% during 2018-2020. According to ConsumerIntel360’s Q4 2020 Global Plant Protein Survey, plant protein in India is gaining traction among health-conscious consumers in recent years. Large consumer food companies are launching plant-based alternatives to cater to the changing consumers' preferences. New product developments and a rising number of product launches in this segment are changing the overall outlook of the plant protein industry. The market growth has been also fueled by the ongoing COVID – 19 pandemic. The demand for plant protein products is expected to increase significantly over the short to medium term. Plant protein industry is expected to continue to grow in India over the forecast period. It is expected to record a CAGR of 29.0% during 2021-2027. The plant protein consumption in the country will increase from US$ 568.3 million in 2020 to reach US$ 3490.0 million by 2027. Scope This research report provides in-depth analysis of plant protein industry in India, providing white space / gap analysis, product innovation, product claims analysis, and brand share analysis, competitive landscape, market size across 50+ segments. Below is the taxonomy, providing detailed scope of coverage. India Plant Protein Market Dynamics – Strategy & Innovation • Competitive Landscape Snapshot • White Space / Demand Gap Analysis by Product Category • Brand Share by Product Category • Key Innovative Launches • Insights on Market Dynamics India Plant Protein Market Size by Ingredients • Soy • Pea • Beans & Lentils • Hemp • Flaxseed, Pumpkin & Other • Brown Rice • Quinoa • Spirulina & Seaweed • Nuts • Other India Plant Protein Market Size by Product Categories • Nutrition Supplements • Protein Bars • Sports Nutrition • Meal Alternative • Dairy Alternatives • Meat Alternatives • Bakery Products • Infant Formulas • Other India Plant Protein Market Size by Functional Segments • Ready to Mix • Ready to Eat • Ready to Drink • Ready to Cook India Plant Protein Market Share Analysis by Sales Channels • Online • In-Store India Plant Protein Market Share Analysis by Type of Retail Outlet • Pharmaceutical & Medical Store • Grocery Retailers • Health and Wellness Stores • Specialist Sports Store India Plant Protein Market Size by Retail Sales Pricing • Premium • Mid-Tier • Low End India Plant Protein Market Size by Cities • Tier 1 Cities • Tier 2 Cities • Tier 3 Cities India Plant Protein Consumption by Demographics • Age • Gender • Income Key Plant Protein Brands in India (based on consumer popularity) • Borges • CAFE HOUSE • CLIF BAR • Cowvathi • Dabur • Del Monte • Dr. Berg’s • EAT Anytime • Edward & Sons • Flex Protein • GoodDot • Goodmylk • Granarolo • HealthOxide • Kapiva • Kivu • Life Roots • Mili • Mimmo Organics • Mojo Bar • MuscleBlaze • MyFitFuel • MyProtein • Naturade • Natures Velvet • Now Foods • Nusobee • Olena • Optimum Nutrition • OZiva • Pintola • Plant Power • Plix • Protinex • RiteBite - Max • Sain • Sampoorna Satwik • Similac • So Good • Sofit • Soyfit • SoyFresh • STRIVE • The Good Food Company • True Elements • True Supplements • Urban Platter • Vega • VegOChef • Wellversed • Yogabar Read full story @ https://bit.ly/3ALYkQ4
Is it worth using Prozac (fluoxetine) as an antidepressant? Find out More!
Prozac is an antidepressant. It's also known as fluoxetine, which is its generic name. Prozac (fluoxetine) is efficient in improving your state of mind, energy levels, sleep, and appetite. This medication is likewise valuable in lessening fear, undesirable considerations, and tension. Prozac (Fluoxetine) is readily accessible as a liquid, tablet, capsule, and long-acting capsule with delayed release. It is advisable for grown-ups and can sometimes be used for children aged 10 years and older. What is Prozac (Fluoxetine) used for? Prozac (Fluoxetine) is an FDA-approved medication. It has been used to treat major depressive disorder (in people aged eight and up), panic attacks, eating disorders (bulimia and binge-eating disorders), bipolar disorder, and premenstrual dysphoric disorder. For treatment-restricted depression, Prozac (Fluoxetine) is also used in conjunction with olanzapine. Prozac (fluoxetine) non-FDA-authorized applications incorporate social anxiety disorder (also known as social phobia), borderline personality disorder, post-traumatic stress disorder, Raynaud phenomenon, and selective mutism. Is Prozac (Fluoxetine) an SSRI? Prozac (Fluoxetine) belongs to the selective serotonin reuptake inhibitors (SSRIs) class of antidepressants. Selective serotonin reuptake inhibitors (SSRIs) are considered "selective" because of their little impact on dopamine or norepinephrine. They exert their therapeutic effect by inhibiting serotonin reuptake. Prozac (fluoxetine) was the first SSRI to be sold in the United States. It has received significant interest among the press and has reduced the long-term stigma and dread of using antidepressants. Over 100 million individuals globally take selective serotonin reuptake inhibitors (SSRIs). One in ten people in the US and one in four women between 40 and 50 years old is supposed to take SSRI to improve their moods by enhancing their brain serotonin. What Does Prozac (Fluoxetine) Do These medications are supposed to operate by boosting serotonin levels, a mood-enhancing neurotransmitter in the brain. These drugs increase the accessibility of serotonin at synapses (associations between brain cells known as neurons) by forestalling the reuptake of serotonin by neurons. How Long Does it Take For Prozac (Fluoxetine) to work Because of its long half-life (4 to 6 days), the initial impact arises within two weeks to about a month. You'll likely continue to take Fluoxetine (Prozac) for several months after you feel better. Most specialists suggest you take antidepressants for a half year to a year after you presently don't feel depressed. Halting before that time can make anxiety return. Prozac (Fluoxetine) Dosage Peruse the medication guide given by your drug specialist before you use Prozac (Fluoxetine) and, each time, you get a top-up. If you have any inquiries, ask your primary care physician or drug specialist before taking this medication. The Prozac (Fluoxetine) dosage is determined by the patient's age and the treatment's goal. The average adult dose of Prozac (Fluoxetine) is 20 milligrams, given by mouth once daily in the morning. If the symptoms do not improve after a few weeks, specialists can increase the dose up to 60 mg. Geriatric or patients with co-morbidities may need to take Fluoxetine (Prozac) at a lesser dose or less frequently. The maintenance dose of Prozac (Fluoxetine) is 20-60 mg per day, while the highest dose is 80 mg. If you are using this medication twice a day, your doctor may tell you to take it once in the morning and then again in the afternoon. An individual who is taking a delayed-release oral capsule to treat depression will take once a 90 mg delayed-release oral capsule a week. If you're taking Prozac (Fluoxetine) in liquid form, use special measuring equipment to make sure you get the proper dose. Use a measuring spoon instead of a household spoon to ensure you get the right dose. What Should I Do If I Miss A Dose Of Prozac (Fluoxetine)? On the off chance that you sometimes neglect to take a dose, don't stress. Take your next dose the following day at the typical time. Never take two doses simultaneously to compensate for a failed to remember one. Prozac (Fluoxetine) Side Effects Prozac (Fluoxetine), like all drugs, can lead to negative consequences in some people, although many people experience no or moderate side effects. As your body adjusts to Fluoxetine (Prozac), many of the most typical harmful effects will fade away. Headaches, anxiety, insomnia, nausea, stomach discomfort, dry mouth, sleepiness, dizziness, trembling, yawning, lethargy, exhaustion, agitation, reduced sexual desire, difficulty or inability to climax, and ejaculation problems are all common side effects of Prozac (Fluoxetine). Joint discomfort, swelling of the face, tongue, and lips, QT prolongation, convulsions, glaucoma, redness of the eye, irregular heartbeat, breathing problems (dyspnea), and serotonin syndrome are all serious but rare side effects of Prozac (Fluoxetine). Prozac (Fluoxetine) Drug-Drug Interactions Medicines that cause bleeding, bruising, or act as blood thinners may react with Prozac (fluoxetine) including, antiplatelet drugs and warfarin. Taking MAO (monoamine oxidase inhibitors) alongside this prescription could cause a dangerous (potentially fatal) drug interaction. Patients should avoid MAO inhibitors for at least two weeks before and after Prozac (fluoxetine) treatment. When to begin or stop using this medicine, consult your doctor. For medicines that affect your heart rate, avoid taking Prozac (Fluoxetine) with them. It may interact with the medication and cause an elevated or abnormal heart rate. Antipsychotics, other SSRIs, and serotonergic drugs like lithium and St. John's Wort should not be combined with Prozac (Fluoxetine). They may cause severe drug-drug interactions. Prozac (Fluoxetine) In Pregnancy And Breastfeeding Prozac (Fluoxetine) transfers to the breast milk in a moderate amount. There is a low risk of harm to the infant according to the limited data available. The general recommendation however is to avoid unless necessary during lactation. It's significant for you and your child that you stay well during your pregnancy. If you become pregnant while taking Prozac (Fluoxetine), address your primary care physician. Try not to quit taking your medication except if your PCP advises you to. Experts have associated Prozac (Fluoxetine) with a modest increase in the chance of complications for your potential child. However, if you don't get help for your depression while you are pregnant, you're more likely to have issues. Offer your significant criticism with us on the off chance that you discover this subject instructive and need to study drugs used in emotional wellbeing. Or, if you are experiencing any mental health disorders, counsel our organization as it's anything but a group of specialists, clinicians, and advisors to take care of you.
High Healthcare Expenditure To Drive The Growth Of The Operating Room Management Market
The pandemic has led to a temporary ban on elective surgeries across the globe, which resulted in cancellations of elective surgeries worldwide. According to a report published by researchers of CovidSurg Collaborative, around 28 million surgeries were canceled across the globe during 12 weeks of peak disruption during the COVID-19 pandemic.   To handle the increased surgical volumes, hospitals are increasing OR hours and focusing on better utilization of OR. The COVID-19 will positively impact the ORM software market. It will increase the adoption rate of ORM software as most hospitals will now focus on increasing capacity by using technology to improve efficiency.  The overall cost of healthcare delivery has grown significantly over the last few decades, mainly due to increasing health insurance premiums, the rising demand for quality healthcare services, the rising geriatric population, and the increasing incidence of chronic disorders.  Another important factor attributing to rising healthcare costs is the high dependency on traditional and outdated methods such as paper-based patient records, which leads to an increase in readmission rates, medical errors, and administration costs.  Different governments and healthcare systems worldwide are now focusing on controlling rising healthcare costs by minimizing patient readmissions, medical errors, and administration costs with the effective utilization of various healthcare IT solutions. Operating rooms or ORs account for 40% of the total hospital expenses and constitute ~70% of the total revenue generated.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175407912 The adoption of ORM solutions has been particularly affected by its high installation and maintenance costs. ORM software, when once installed, also requires to be regularly updated as per the user’s requirement and software enhancements, thereby presenting recurring expenditure. Additionally, the maintenance of high-end IT-enabled systems typically costs more than the software itself.  The annual maintenance cost is estimated to be 20-25% of the initial cost of the software licenses. Subsequently, it can be expected that the high costs incurred from the purchase, installation, maintenance, and upgrade of ORM software and solutions may negatively affect their overall adoption among end-users, thus restraining market growth to a certain extent.  Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. According to the World Economic Forum, these emerging economies will account for around one-third of the global healthcare expenditure by 2020. More than half of the world’s population resides in India and China, owing to which these countries are home to a large patient base. The increasing burden of cancer, improvements in healthcare infrastructure, a less-stringent regulatory environment, and growing medical tourism are encouraging players in the operating room management market to increase their presence in emerging countries. Owing to the expansion of the patient population base, the number of hospitals and surgical centers is also expected to increase in emerging countries in the coming years. Also, currently, governments in these countries are undertaking initiatives to expand and modernize their respective healthcare infrastructures.  The number of independent health care providers has been decreasing as most healthcare providers are turning to mergers, acquisitions, and partnerships and are functioning under a health system rather than operating independently. On a 15-year basis, the percentage of hospitals functioning under a health system has increased from approximately 50% to approximately 65%. Today, over 70% of hospitals are operating as part of a health system rather than independently.  Data management communication solutions accounted for the largest share of the operating room management market in 2019 owing to the benefits such as easy sharing of patient status in perioperative care phases, tracking of the schedule compliance, and sharing of the media and information related to cases within different operating rooms or external hospital departments.  The high growth of this segment can primarily be attributed to advantages such as scalable data storage, scalable computing power, machine-learning capabilities, and faster data transfer between organizations of cloud platforms.
How To Make Use Of Basil Seeds For Health Benefits
Basil is a familiar spice and one found in many cuisines. Basil is derived from the Latin Basilicum which means "grass plant." Basil has a pungent and spicy taste that is used in a variety of cooking styles. There are variations of basil based on the regions where it is grown, but all types share the same taste and smell. Basil is also used as an added ingredient in food and medicine for a variety of ailments. Basil is used in India to treat many ailments including cardiovascular problems, respiratory infections, sinusitis and diarrhoea. It is used to reduce fever and alleviate coughs as well as to treat skin problems such as acne and rashes. Basil's anti-inflammatory properties help reduce swelling and reduce pain. Basil also helps alleviate discomfort from stomach cramps related to menstruation as well as reduce coughing and sore throats caused by bacteria. The pungent and aromatic nature of Basil seeds makes them good for digestion. Long-term consumption can benefit the digestive system. Digestive disorders can be reduced by including basil seeds in the diet. Basil Seeds in Urdu means "guard the duodenum" because it has fibres that protect the intestines from germs and other harmful elements. The seeds contain soluble and insoluble fibres that are essential for proper digestion. These fibres control blood sugar levels as well as cholesterol levels. They also contain sulphur-containing compounds that regulate blood sugar levels. The presence of sulphur-containing compounds aids in controlling blood sugar levels after the ingestion of foods. You can add basil seeds to the cooking water before you add any spices or herbs to your meals. Basil can be used both in soups and in sauces. You can soak some of the seeds into a container of water and drink this as an ingredient of your hot beverage such as tea or coffee. You can add dried, unsweetened, crushed or chopped basil seeds to salads or make a delicious herb salad. You can even sprinkle the leaves on top of cooked foods or in salads. You will find many interesting ways to use dried, unsweetened and chopped basil seeds or the whole plant to make interesting and tasty recipes. You can soak dried basil seeds or the whole plant to add flavour to soups, stews, salads and vegetable dishes. You will be able to use basil seeds or the whole plant in many different recipes because of their versatility.
How COVID-19 Impacted on Nutraceutical Packaging in Healthcare Industry ?
COVID-19 Impact on Nutraceutical Packaging in Healthcare Industry The COVID-19 pandemic has impacted the food and beverages industry including the nutraceutical market by up surging in their consumption globally. Each and every segment of nutraceutical industry has been impacted either positively or negatively due to the COVID-19 pandemic. The Nutraceutical packaging market is subjected to have the positive impacts due to the sudden outbreak of COVID- 19. This is mainly due to the consumer awareness about the importance of consuming the nutraceuticals in order to boost their immunity to fight the pandemic period. The demand for the nutraceuticals has been increasing across the globe due to the changing lifestyle of the health conscious consumers. This increase in the demand for the nutraceuticals have positively affected on the nutraceutical packaging market. AFTERMATH OF COVID-19 AND GOVERNMENTS INITIATIVE TO BOOST THE GROWTH OF THE MARKET The aftermath of the COVID- 19 has a very positive impact on the market of the nutraceutical packaging across the globe. As the consumers are more incline to buy health and wellness products such as nutraceutical products which further increased the sales and revenue of the market players. The post pandemic period people are more concerned towards the product’s safety and shelf life which further drive the demand for advanced and innovative packaging materials for nutraceuticals. Also, with the growing awareness and growing social media nutritional trends influencing population all around the world will increase drive the demand for nutraceutical which will further boost the growth of global market. Many governments have taken initiatives for the nutraceutical packaging as they have been focusing on ways to improve the consumer’s health and wellness. The government initiatives to support industries in order to manufacture innovative packaging products will boost the growth of the market. For example, · European Union (EU)- funded project NanoPack aims to develop packaging solutions that increase product life after packaging by using novel anti-microbial surface application on the food packaging product surface. The Nanopack antibacterial film extends the shelf life of the product by two days. This two day increase in shelf life increase product stability by 40%. Therefore, such initiatives taken up by the governments which aim to help the manufacturers to manufacture safe products for the nutraceutical packaging will propel the growth of the market. STRATEGIC DECISIONS OF MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE To deal with the COVID-19 outbreak challenges many nutraceutical packaging market players are creating new strategies. It is predicted that these strategies are providing high chances to escalate up company revenue and its growth in the forecast period. Similarly, growing opportunities in innovative packaging solutions is attracting a larger consumer base for the nutraceutical packaged products. Increase in the demand for the nutraceuticals has made companies to launch the new products in spite of the COVID- 19 challenges and to gain a larger market share. Despite of the COVID – 19 pandemic outbreak, the manufacturers have been creating new opportunities by themselves by participating in exhibitions in order to spread the awareness about the nutraceuticals and their nutritional benefits which helps in boosting the immunity of the consumers. For instance, · In 2021, MJS packaging announced that they will exhibit for the first time since the start of COVID- 19 pandemic at the 2021 Cannabusiness international market place Michigan summit and expo in Michigan. Therefore, such product launches, exhibition of the products at the expos and vents in order to increase their consumer base are the strategic decisions which are taken up the market players to gain larger market share. PRICE IMPACT The COVID-19 had a terrible impact on the global economy. Many establishments have to remain shut while others scale down their operations or put on hold expansion plans as they survive the unprecedented crisis. The other impact of the COVID-19 pandemic outbreak is the delay or fluctuation of raw material supply for nutraceutical packaging manufacturing. This fluctuation has resulted in increase in price of raw material, which has impacted the prices of nutraceutical packaging products. IMPACT ON DEMAND There is a rapid increase in demand for the nutraceuticals increasing popularity for the nutraceutical packaging as well. Demand for the increased shelf life of food products across the globe is expected to increase the growth of the market in the COVID-19 period as well. There is an increasing consciousness about health and weight management is playing a crucial role in the demand for the global nutraceutical packaging market. On an average, the consumers have increased have increased their monthly spending on vitamins, minerals and supplements products by 10-15% since the COVID- 19 began. The increase in the awareness among the consumers about the consumption of the nutraceuticals is that they can build the immunity that is highly required in the COVID- 19 pandemic period has positively affected on the nutraceutical packaging as well. With the rise in the consumption of the nutraceutical in order to maintain the good health and fitness, the demand for the nutraceutical packaging also increased. Therefore, there has been a constant increase in the demand for the nutraceuticals which positively affected on the nutraceuticals packaging market as the packaging of the vitamins, minerals and other dietary supplements is the major factor that attracted the attention of the consumers. IMPACT ON SUPPLY CHAIN During the pandemic situation, the supply chain was majorly disrupted due to a lack of resources and transportation. Also, the governments across the world have implemented various restrictions and lockdowns to prevent the spread of the disease. In the same way, many governments have restricted the movement of goods across the countries and the entire supply chain was distorted. Owing to the disrupted supply chain, the transportation of raw materials has been interrupted and the production of nutraceutical packaging products was halted. Similarly, the manufacturers aren’t able to visit the customers such as nutraceutical companies to provide them with the packaging materials due to the implementation of lockdowns across the various parts of the world. Thus the demand for nutraceutical products has been tremendously increasing whereas the packaging materials production has been disrupted. As a result, the COVID- 19 pandemic has negatively impacted on the supply chain of the nutraceuticals packaging market. CONCLUSION COVID- 19 pandemic has taken a toll on the population and economy. A collaborative effort on governments, public health departments and hospital fraternity to fight corona virus has led to the economic slowdowns, lockdowns and extreme public safety measures. Due to the increasing health conscious ness among the consumers, the demand for the nutraceuticals has been increasing constantly in the COVID – 19 pandemic periods. This is mainly because of precautionary measures which are followed by the consumers for the COVID-19 which in involves the intake of nutraceuticals. However, the supply chain has disrupted during the outbreak scenario because the demand is more for these products. As unlocking of the lockdown being started in various regions of the world, it is expected that the supply chain became normalized for the market.
RIMS Trauma Hospital
Every day people enter the gates of Rims Trauma Hospital to find themselves or their loved ones. With an unwavering commitment to best practice that meets international standards, regulations and quality systems, we ensure that patient needs are met satisfactorily under one roof. Rims Trauma Hospital is located in the heart of the bustling city of Karachi on Shahrah-e-Faisal Road, near Nursery Bridge. Thanks to this unique location it has easy access to all the city quadrants. RIMS Trauma conceived as the start of an arts hospital with the vision of providing low-cost health care at an affordable cost to all economic classes. Over the years, the hospital has become the largest hospital in the country with over 100 beds. And we have the largest number of beds and ventilators in town. the hospital excels in all aspects of medicine, surgery, diagnosis and medical support services. RIMS Trauma has more than 15 items. Considering patient care as a priority, we provide 24-hour emergency services, intensive care, outpatients, outpatients and childcare facilities not only in the city but also in patients from remote parts of Sindh, Balochistan, Khyber Pakhtunkhwa and Punjab. RIMS Trauma pioneered in many special areas. We have also developed other facilities such as the Physiotherapy Development Unit, Dental Care and implantation procedures. These courses are led by specialized and highly trained doctors. Rims Trauma Hospital is renowned for its many surgical and surgical procedures. We have a close relationship with the College of Physicians and Surgeons of Pakistan. We also enjoy the privilege of being the cheapest hospital in the city. We are proud to serve with the greatest compassion, compassion and care in the event of emergencies, accidents or disasters in the city. We believe that anyone and everyone who needs health care is our problem. The doors of Rims Trauma Hospital are always welcome for those in need. Inexpensive consultation with treatment and the latest in-country and national patient services. Address PECHS Block 6, Sharah-e-faisal, Near Nusery Bridge, Karachi, Pakistan PTCL: 021-34311340-3 Email: info@rimstrauma.com
How COVID-19 Impacted on Bevacizumab in Healthcare Industry ?
COVID-19 Impact on Bevacizumab in Healthcare Industry In the city of Wuhan, China the Coronavirus disease (COVID-19) outbreak is originated. Coronavirus disease (COVID-19) has spread across the globe, with large number of cases having been reported worldwide. The Coronavirus disease (COVID-19) pandemic is not only creating health crisis but also it is unfavorably affecting on healthcare, economies and pharmaceutical sector as well as at their core. As COVID-19 is the infectious disease, its spread is endless. It have causes a nationwide outbreak as well as public health crisis. Cancer treatment and therapies drugs manufacturing companies have also faced some difficulties in manufacturing and distribution of the drugs and medication due to locked down, supply chain and social distancing restrictions. In some recent studies, it was stated that Bevacizumab, an anti-VEGF drug, approved by the FDA and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema which have increased its demand in the market and also increasing cancer patients have also driven the market demand and supply. PRICE IMPACT The Coronavirus disease (COVID-19) pandemic has an enormous impact on the global economy market. The demand for cancer treatment products has increased along with its prices in the treatment of COVID. In addition, the sum of research and development and marketing, selling, and administrative expenses have been increased in 2020, which is driven primarily by the development expenses for COVID-19 therapies. For instance, Bevacizumab plus standard care markedly improves the oxygen ratios in COVID 19 patients and shows improvement in oxygen-support status, patients were discharged, and none of the patients have shown worsen oxygen-support status nor die. Also, the demand for cancer treatment products will be increased, and the products are upgraded by top importer countries like U.S., which have increased the sales and prices of the bevacizumab. For instance, The drug Avast in (bevacizumab) has been increased to $842 for a supply of 4 milliliters dose in 2020. Due to the increase in demand, the use of bevacizumab in the COVID treatment and increase in production and manufacturing expenses have contributed to product prices. IMPACT ON SUPPLY CHAIN The COVID-19 pandemic has transformed many organizations’ business environment; several problems, including export and travel ban by some producing countries and lockdowns that have caused producers to (temporarily) shut down, have disrupted supply access. Difficulties or delays in manufacturing, sales, or marketing; supply disruptions, shortages, or stock-outs at our facilities; and legal or regulatory actions all are caused due to the COVID 19 pandemic. But it does not affect the sales and supply of the drug bevacizumab that much because of the rise in new diagnoses or cancer and the efficiency of the drug in treating the COVID patients. These are some of the reasons which have maintained the supply of the drug throughout the year With the rise in demand and supply of the drugs, many manufacturing companies have launched their new products, which have increased their sales. For instance- · The sales of the drug MVASI (bevacizumab) from the manufacturing company Amgen Inc. have increased more than 20% in the U.S., which is USD 121 million in 2019 to USD 650 million in 2020 and for the rest of the world, drug sales increased from USD 6 million in 2019 to USD 142 million in 2020. This increase in the supply of the drug is with the increasing treatment for cancer. · Similarly, the sales of the global segment generics, which include biologics drugs such as bevacizumab of the company Dr. Reddy’s Laboratories Ltd, have also been increased from USD 1,858.27 million in 2019 to USD 2,079.96 million in 2020. This increase in sales is due to the increase in healthcare and Research & Development due to COVID 19. IMPACT ON DEMAND Coronavirus disease (COVID-19) is an infectious disease caused by a SARS-CoV-2 virus, while a large population is affected by this COVID-19 virus. Coronavirus disease 2019 (Covid-19) is an ongoing worldwide pandemic; nearly all the countries have taken initiative action under locked down and social distancing restriction. Reduction in cancer treatment across the globe has affected the demand for cancer treatment and their drugs like bevacizumab, especially in the first quarter, but after the second quarter of 2020, the demand for the drug has increased because of its Efficacy and tolerability of in patients with severe COVID-19. For Instance- Recent evidence revealed higher blood Vascular Endothelial Growth Factor (VEGF) levels in COVID-19 patients compared with healthy controls. VEGF is considered the most potent vascular permeability inducer. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004, and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema. Also, the increase in cancer patients and the rise in the demand for the treatment of various types of drugs have propelled the market demand and sales of major market players. For instance, · There is an increase in the sales of biosimilar drugs which includes bevacizumab, for major market players. For instance, the manufacturing company Pfizer Inc., the sales of biosimilar segment is increased from USD 1,527 million to USD 911 million with the increase in demand for the drugs in COVID patients and the cancer treatment. STRATEGIC DECISIONS FOR MANUFACTURERS A large population is affected by this COVID-19 virus, and its spread is expanding worldwide for the last few months. To deal with the COVID-19 outbreak challenges, many bevacizumab and biosimilar market players are creating new strategies. The company is now opting for digital media such as telecommunication, mobile applications, webinars, and other digital media to support patient requirements to tackle the pandemic situation and increase the company sales with the increasing demand and growth. Moreover, to accomplish the market demand, small market players are utilizing the partnership agreement strategy. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. They have launched new products and formed strategic alliances with each other to carry on the supply during the pandemic. For instance- · In 2020, Amgen Inc. had advanced their innovative pipeline, successfully integrated MVASI, acquired in November 2019, a biosimilar to Avast in (bevacizumab), and has advanced their international expansion continued to provide an uninterrupted supply of their medicines globally through the COVID-19 pandemic · In May 2020, the Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unrespectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy CONCLUSION It can be concluded that the COVID-19 pandemic has a positive impact on the global bevacizumab market with the increase in the price, supply, and demand of the bevacizumab. However, in the crisis call, pharmaceutical market players, government bodies, and healthcare organizations work closely with healthcare professionals, customers, and patients for the betterment of public health and to fulfill the demand. However, companies and government bodies exclusively concentrate on how they can make the most effective and best contribution to control the spread of the virus and save lives. They are also ramping up the production of essential medication to a new level and ensure that speed doesn’t affect or destroy the quality of products.
Significant COVID-19 Impact on Juvenile Polyposis Treatment in Pharmaceutical Industry
COVID-19 Impact on Juvenile Polyposis Treatment in Pharmaceutical Industry The first case of the COVID-19 pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its highly infectious and contagious nature and the lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be face d by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries and the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, South America, and Africa up to the Middle East. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) due to its increased spread worldwide. The outbreak of COVID-19 has had a great impact on the healthcare and pharmaceutical industries and a major impact on the global juvenile polyposis treatment market. Juvenile polyposis syndrome is a genetic disorder characterized by the growth of polyps along the gastrointestinal tract lining. Juvenile polyposis treatment can be done in two ways. When many polyps are present, surgery may be done to remove a part of the stomach or intestine. When there are fewer polyps, they can be removed during endoscopic examination. The decreasing number of surgical and non-surgical procedures during the pandemic will negatively affect the growth of the global juvenile polyposis treatment market. PRICE IMPACT The COVID-19 had a terrible impact on the global economy. Many establishments were forced to remain shut while others had to scale down their operations or put on hold expansion plans as they tried to survive the unprecedented crisis. Another impact of the COVID-19 pandemic is the delay in surgical and non-surgical procedures to treat selective diseases. Patients are preferring alternative treatment procedures that have no requirement for physically appearing in hospitals or clinics. Consequently, the demand for medical devices used to treat juvenile polyposis has decreased due to the decrease in various surgical and non-surgical procedures during the pandemic. For instance, · According to a study performed by BMJ Journals in the U.K., a weekly average of 35,478 endoscopic procedures were performed during the pre-COVID period. After the COVID-19 pandemic, these numbers reduced by 12 percent · According to an article by PMC, diagnosis of colorectal cancers was considerably delayed during the pandemic, which had a huge economic and workload burden on the gastroenterologists, surgeons, and oncologists Suppose the COVID-19 keeps on spreading like this for a long period. In that case, it is estimated that the demand for medical devices like endoscopes and colonoscopes which are used to treat juvenile polyposis, will downgrade by top importer countries. Suppose the lockdown continues to stretch for a longer period than anticipated. In that case, a huge drop is expected in non-surgical and surgical procedures worldwide, including the treatment of juvenile polyposis. Consequently, demand for the medical devices used in the procedure is anticipated to be minimized, which may decrease the price of the overall juvenile polyposis treatment procedure. Thus it is predicted that COVID-19 negatively affects the price of the juvenile polyposis treatment market. IMPACT ON DEMAND Coronavirus disease is an infectious disease that is caused by a SARS-CoV-2 virus. Currently, a huge population pool is affected by this COVID-19 virus. Coronavirus disease causes acute respiratory illness, ranging from mild to severe pneumonia with respiratory failure, and in rare cases, it is also associated with major cardiac complications. In order to reduce the spread of COVID-19, nearly all the countries have taken initiative action by lockdown and social distancing restriction. Due to affirmative restrictions, sudden shrink occurred in various surgical and non-surgical procedures requiring the patients' physical presence. Reduction in surgical and non-surgical procedures across the world has adversely affected the demand for the treatment of juvenile polyposis. Due to lockdown and social distancing restrictions, most patients prefer virtual vising through video calling or telehealth video visiting. Telehealth video visits are demanding alternative treatment such as medication for the treatment of certain diseases. Consequently, the growth of the juvenile polyposis treatment market is anticipated to downgrade as this procedure needs the patient to be physically present. For instance, · According to CDC, in 2019, 43 percent of the health centers were capable of providing telehealth services, while in 2020, during the COVID-19 pandemic, it was reported that 95 percent of the health centers were providing telehealth services · According to May 2020 article published by PMC, COVID-19 had a huge impact on surgical practice. There was a huge decline in the number of surgical procedures taking place, and also the surgeons are recommending safe, non-surgical alternative options to treat their patients during the pandemic IMPACT ON SUPPLY CHAIN COVID-19 has led to a disruption in the supply chain of medical devices, which are essential for treating and diagnosing juvenile polyposis syndrome. In different countries, diagnoses of other diseases have slowed down due to increased pressure to diagnose COVID-19. This led to a significant delay in diagnosing juvenile polyposis syndrome, which ultimately reduced the number of treatment procedures. The COVID-19 pandemic has truly transformed some organizations' business environment; the organizations' supply chain has been hampered by several issues, including export and travel restrictions by some countries and lockdowns that have forced suppliers to shut down in the majority of the cases temporarily. For instance; · According to an article by The Hindu published in May 2021, China holds the majority of the market for raw materials, and unfortunately, the pandemic leads to global restriction along with series of lockdowns which leads to disrupted supply chain To minimize supply chain crises, healthcare organizations have been firmly monitoring the supply chain with the assumption that the COVID-19 outbreak may adversely impact the supply chain of a medical device or equipment. This includes shortages of endoscopes and colonoscopes required to treat juvenile polyposis or potential disruptions in its supply chains. To manage an adverse situation, many organizations have looked forward to improving and diversifying the supply chain model in all aspects. A diversified supply chain model anticipated minimizing the export of medical devices and equipment and increasing end-to-end visibility. The COVID-19 pandemic has shown various supply chain management methods, which may remain effective within a remote working environment. STRATEGIC DECISIONS FOR MANUFACTURERS COVID-19 can hamper the production and supply chain of endoscopes and colonoscopes, which are used in the treatment procedure of juvenile polyposis. Still, it also provides companies to improve their business by different means. Different companies made different strategic decisions to maintain their supply chain constantly and reduce the spread of the virus among their employees. They made proper decisions to maintain a safe work environment. For Instance, · Olympus, a leading manufacturer and supplier of endoscopes and colonoscopes, has maintained proper supplies during the pandemic while being vigilant about the risk. They have worked closely with infection prevention societies and regulatory agencies to address this important human health concern · Stryker, a major manufacturer of endoscopes, has been closely monitoring the impact of COVID-19 since it was first reported, and they have taken action to ensure proper safety for their customers, employees, and communities This signifies that despite the pandemic situation, different strategic decisions made by these companies would make their business grow. CONCLUSION With the mystery around the disease remains unsolved at many levels, the management of healthcare becomes imperative. The safety of the people is paramount, and initiatives are being taken to get people through this unprecedented scenario. Though it is estimated that the pandemic will negatively affect the growth of the global juvenile polyposis treatment market, the strategic decisions made by different companies, governments, and other organizations will help out in handling this crisis eventually.
COVID-19 Impact on Primary Pulmonary Hypertension (PPH) Treatment in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Primary Pulmonary Hypertension (PPH) Treatment in Healthcare Industry Coronavirus (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis. COVID-19 is a type of ARDS (acute respiratory distress syndrome) that originated in Wuhan, China. Due to its highly infectious nature, this disease is still spreading throughout the world. Although vaccines are now available in the market, due to various challenge (large scale manufacturing of novel vaccine, national vaccination protocol, availability of the vaccine, new variants of COVID-19, lesser quarantine strictness), it has not been able to slow down or stop the virus from spreading globally. In the treatment of COVID-19 patients with ARDS, Prostacyclin (a vasodilator), primarily known for treating pulmonary arterial hypertension (PAH), has shown promising results in many studies. Price Impact COVID-19 pandemic has a huge impact on every market globally. The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Increasing yearly demands and using Prostacyclin in the treatment of ARDS (COVID-19) patients has affected all major manufacturers of the drug. For instance: · Remodulin (Treprostinil) a drug sold by United Therapeutics Corporation. A standard single dose of 20 milliliters 1 mg/ml Remodulin cost has gone from USD 45 (2017) to USD 69.94 (2021) Prostacyclin manufacturing leaders (United Therapeutics Corporation, Janssen, GlaxoSmithKline, and Sandoz) worldwide face export restrictions that directly affect the product's market cost. An additional increase in demands due to COVID-19 treatment is anticipated to impact significantly the forecast period. Impact on Demand There is no specific and approved treatment to treat the Coronavirus disease (COVID-19), apart from prevention by social distancing and, now, using vaccination. However, inhalation of prostacyclin vasodilator has been shown to work synergistically with COVID-19 medication to recover ARDS patients on ventilators. Coupled with the uncapped spread of the virus. For instance: · Hamad Medical Corporation - Inhaled Iloprost (Phase II) for Suspected COVID-19 Respiratory Failure (ILOCOVID) Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80% of the population aged 65 and above have at least one chronic condition: high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease. Hence the market for global PPH treatment is speculated to boom in the forecasted period. Impact on Supply Chain COVID-19 restrictions and lockdown have affected the supply chain of all manufacturing firms globally. Prostacyclin (Europe and Asia-Pacific) primary manufacturer was under complete lockdown, causing manufacturers to shut down (temporarily) supply chains. For instance: · By the end of July 2020, nearly 90 countries had introduced export restrictions due to the COVID-19 pandemic, according to the WTO. Since January 2020, countries have taken more than 197 actions banning or limiting the export of certain products, according to Global Trade Alert · Overall, the U.S. exports to the world were down USD 8.47 billion when comparing the first two months of 2021 to the same period of 2019 To tackle these unique challenges, manufacturers are looking for innovative ideas and complete re-thinking of supply chains. Remote work has been another unique restraint put forth by mandatory lockdown, which requires a completely novel approach towards supply chain processes. Strategic Decisions for Manufacturers Sudden demand surge and lockdown caused temporary roadblocks. The shutdown of international transport and supply chains also requires immediate remedies. Manufacturers, to combat challenges presented by the COVID-19 pandemic, devised various ideas. New product launches, remote working environment, recommencing supply chain manufacturing with social distancing restrictions are some strategic decisions made by manufacturers For instance: · Beth Rhodes, Vice President, Global Supply Chain & Alliance Management at United Therapeutics said, “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients. Remunity is a small, discreet pump that delivers Remodulin in prefilled cassettes that are delivered directly to patients, offering significant improvements over current subcutaneous pumps” – CONCLUSION It is predicted that COVID-19 has a major impact on the primary pulmonary hypertension (PPH) treatment market. Increased PPH drugs (Remodulin, Flolan, Veletri, Ventavis) and strict trade policies globally have pushed manufacturers into considering new and compatible market strategies. However, increase the prevalence of pulmonary hypertension, robust drug pipeline, and changing lifestyle, drives the global primary pulmonary hypertension (PPH) treatment market. Moreover, technological advancement in treatment & diagnosis and growing genetic mutation-related disorders also boost up market growth. But adverse effects related to the treatment, unknown causes behind the disease, and difficulty in diagnosis of primary pulmonary hypertension (PPH) treatment may hamper the global Primary pulmonary hypertension (PPH) treatment market.
(no title)
ラブドールをトラックの助手席に座らせて運ばせる客 そのうえ、新藤さんは緊急事態宣言下の今年春ごろ、とんでもない“荷物”の引越しもさせられている。その荷物とは、人間と見紛うほどリアルなラブドールである。 いったいどういう状況でラブドールを運ぶことになったんですか 新藤 その客は古い2DKのマンションに住む30代前半の小柄な男性で、一見すると物静かな印象でした。荷物の量自体は普通のひとり暮らしの男性と同じだったんですが、奥の3畳ほどの部屋だけは、なぜかガラス戸が固く閉まったままでした。そこでガラス戸を開けると、アンティーク風の椅子が真ん中にあり、髪が長くて肌の白い人形がフェミニンな服を着て座っていたんです。ものすごく高品質かつリアルなダッチワイフで、最初は人間の女性に見えました。作業員が集まって「あれはなんだ」「人?」「いや人形じゃないか」とヒソヒソ相談したくらいです。 ─たしかに最近のラブドールのクオリティはすごいと聞きます。 新藤 でも、大変だったのはそこからでした。通常の手順通り、セックス人形にプチプチを巻いて緩衝材の布をかけようとしたら、男性が血相を変えて「何をしているんですか!!」と僕の手をガッとつかんだんです。「梱包して運ぼうとしているんですが」と答えると、男性は「それは違うでしょ。普通は人にそんなことをしない」と真剣な表情で言う。なるほど。男性にとってそのラブドールドールは「人」であり「彼女」なんですね。 https://www.saikodoll.com/ セックス人形と並んで座り新居まで 新藤 そういうことみたいです。それで先輩を交えて男性と相談した結果、トラックの座席にドールを乗せて移動することになりました。通常の作業時は運転手、先輩、僕の3人で座席に乗って移動するんですが、僕は機材を運搬する別の車両に乗り、代わりにセックス人形を助手席に座らせて、ちゃんと人間のようにシートベルトも着用させて運びました。 先輩はめちゃくちゃ恥ずかしかったそうです。新居までの移動時間が1時間あまり。その間、作業着姿のおじさん2人がラブドールと並んで座り、ほかのドライバーからジロジロ見られ続けたわけですから。そういう意味では、この男性は本当に迷惑な客でした。
Significant COVID-19 Impact on Hearing Aids in Healthcare Industry
COVID-19 Impact on Hearing Aids in Healthcare Industry The COVID-19 has affected the global hearing aids market. The persistence of COVID-19 for a longer period increased the demand for hearing aids services across the global region. During, COVID-19 pandemic, the countries were expecting a large number of patients with the impaired hearing which results as one of the symptoms of COVID-19 disease. Moreover, the increased geriatric population across the globe with the hearing inabilities due to their age is a major factor driving the global hearing aids market. The rising number of patients suffering from hearing inabilities and hearing loss coupled with the increasing demand for the advanced level and effective technology hearing aids to provide to the patients will boost the growth of the market. The demand for hearing aids for the patients which is a rare symptom of COVID-19 has overall decreased during the COVID-19 crisis. IMPACT ON THE DEMAND OF THE GLOBAL HEARING AIDS MARKET The global hearing aid market was negatively impacted by the pandemic. The hearing care industry is dependent on close customer contact. Due to stringent precautionary measures announced by the government, close human contact was discouraged or required special measures in the clinics and the audiology shops. As a result, less severe hearing loss-related procedures were delayed during the pandemic which impacted the sales of hearing aids. Despite these challenges, manufacturers implemented measures to meet the high demand for timely professional hearing care. Due to product innovation and re-inventing supply chain, major players in the hearing aids market were able to sustain demand and cater to the hearing healthcare market even during the pandemic. INITIATIVES BY THE MANUFACTURERS: There are some important initiatives taken up by the key market players to overcome the COVID-19 impacts on the current market scenario. Some of them include the launch of technologically advanced devices in the global market to meet the growing demand for hearing aids. For instance, In 2020 GN hearing launched Resound ONE that solves one of the most enduring challenges for people with hearing loss. This solution places an additional microphone inside the ear canal with a microphone and receiver in-ear design that uses the unique shape. Manufacturers are trying to meet the growing demand and improving their product portfolio to acquire a larger market share by launching new products that are preferred by the consumers. For instance, · In January 2021, Oticon Inc launched Oticon More, a new hearing aid that builds on the company’s proven brain hearing approach to provide the brain optimum input for better speech understanding with less approach. · In March 2020, Widex launched the moment hearing device. The widex moment has the classic widex signal pathway which is paired with a second ultra-fast signal pathway that adds extra gearing to the platform. Therefore, these innovative launches made by the manufacturers across the market during the COVID-19 and post-pandemic period are expected to increase their sales and revenue by meeting the growing demands of the patients in the market. IMPACT ON THE SUPPLY CHAIN Although there was a demand for hearing aids among consumers around the globe region due to the increasing hearing loss, the COVID-19 has disrupted the supply chain as well as consumer’s willingness to adopt elective healthcare. The COVID-19 has negatively impacted the market supply chain due to the lack of labor and transportation of the raw materials. Due to the sudden outbreak of the COVID-19 pandemic, the governments in the world have declared a strict lockdown to control the spread of disease. This has majorly affected the supply chain as there is not sufficient labor in the manufacturing facilities, resulting in the lack of hearing aid products in the market. Due to the sudden burden of lockdown, the raw materials have not been shifted from the source places by causing a severe scarcity of raw materials for the manufacturers. This has affected the export of hearing aid products to other needful countries. However, in the post lockdown period, the manufacturers have recovered from the scarcity of the raw materials and resumed production. CONCLUSION The sudden onset of the COVID-19 pandemic has resulted in negative impacts on the supply chain of the global hearing aids market. The COVID-19 has caused lots of health issues including the hearing inability in rare cases which increased demand for hearing aids. This is positively impacting the growth of the global hearing aids market as there is an increasing geriatric population around the globe with common hearing problems. However, the increase in the hearing inability diseases among the population due to various reasons such as noise pollutions, genetic disorders among others has increased the demand for hearing aids even in the COVID-19 pandemic.
Fungal Infections Market Foraying into Emerging Economies 2028
Fungal infections market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of fungal infection worldwide and emerging markets are the factors responsible for the growth of this market. Request Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-fungal-infections-market However, increased prevalence of hospital-acquired or nosocomial infections and infectious disease (especially in topical and sun-topical countries), advanced treatment with enhanced penetration of drugs in the skin, and increased awareness related to skin fungal infection will boost up the global fungal infections market. But, excessive use of antifungal agents causes skin damage and other side effects which may hamper the global fungal infections market. Fungal infections are common in the natural world. The infection occurs when an invading fungus takes over an area of the body and is too much for the immune system to handle. Global Fungal Infections Market Scope and Market Size Fungal infections market is segmented on the basis of types, drugs, treatment, route of administration, dosage form, end-users and distribution channel. The growth amongst the different segments helps you in attaining the knowledge related to the different growth factors expected to be prevalent throughout the market and formulate different strategies to help identify core application areas and the difference in your target markets. On the basis of drugs, the fungal Infections market is segmented into corticosteroids, corticosteroid-sparing agents, immunosuppressive, immunomodulator, antifungals and others. Antifungal drugs further segmented into azoles, imidazole, triazoles, anti-metabolites, allylamine and others On the basis of route of administration, the fungal Infections market is segmented into oral, parenteral, topical, vaginal and others On the basis of types, the fungal Infections market is segmented into aspergillosis, blastomycosis, candidiasis, candida auris, coccidioidomycosis, cryptococcus gattii infection, fungal eyes infection, fungal nail infection, histoplasmosis, ringworm, others On the basis of treatment, the fungal Infections market is segmented into antifungal, others On the basis of dosage form, the fungal Infections market is segmented into creams, gels, ointment, solution, lotions, others On the basis of end-users, the fungal infections market is segmented into hospitals, specialty clinics and others On the basis of distribution channel, the fungal infections market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-fungal-infections-market Fungal Infections Market Country Level Analysis Fungal infections are analysed and market size information is provided by country, types, drugs, treatment, route of administration, dosage form, end-users and distribution channel. as referenced above. The countries covered in the fungal infections market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in the Asia-Pacific, U.A.E, Saudi Arabia, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa. Inquiry Before Buy @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-fungal-infections-market Competitive Landscape and Fungal Infections Market Share Analysis Fungal infections market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to fungal infections market. The major players covered in the fungal infections market are Pfizer Inc., AstraZeneca, Eli Lilly and Company, Galderma Laboratories, L.P., Hikma Pharmaceutical PLC, Novartis AG, Johnsons & Johnsons Services, Inc, Astellas Pharma US, Inc., Mylan N.V., and Taro Pharmaceutical Industries Ltd. Among others.
Particle Therapy Market worth USD 1,349 million by 2023 : Technological advancements in the field of Heavy Ion Therapy
The study involved four major activities to estimate the current market size for particle therapy. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter market breakdown and data triangulation was used to estimate the market size of segments and subsegments. According to the new market research report “Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) – Forecast to 2023“, published by MarketsandMarkets™, the global Particle Therapy Market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%. Browse in-depth TOC on “Particle Therapy Market“ 80 – Tables 36 – Figures 138 – Pages Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137 The major factors driving the growth of the Particle Therapy Market are the growing global prevalence of cancer, growing adoption of particle therapy in clinical trials, advantages offered by particle therapy over photon therapy, and the increasing number of particle therapy centers worldwide. The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market, by cancer type, in 2018 Based on cancer type, the Particle Therapy Market is segmented into pediatric cancer, prostate cancer, breast cancer, lung cancer, head & neck cancer, and other cancers. The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market in 2018. The growing incidence of pediatric cancer and the high success rates and minimal long-term risks achieved with particle therapy are the major factors driving the growth of this market segment. Research applications to register the highest CAGR in the global Particle Therapy Market during the forecast period Based on applications, the Particle Therapy Market is segmented into treatment applications and research applications. The research applications segment is expected to witness the highest CAGR during the forecast period. Growing awareness about the research applications of particle therapy systems, development of cost-effective and technologically advanced diagnostic and therapeutic particle therapy systems, and increasing industry-academia collaborations in the field of research are the key factors driving the growth of this segment. Asia Pacific to dominate the Particle Therapy Market during the forecast period The Particle Therapy Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to account for the largest share of the global Particle Therapy Market in 2018, and this trend is expected to continue during the forecast period. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the Particle Therapy Market owing to the increasing healthcare expenditure and growing initiatives to promote the use of advanced particle therapy technologies in Asia Pacific countries. Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=12809137 The major players operating in the Particle Therapy Market are Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), Hitachi, Ltd. (Japan), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy plc (UK), and Danfysik A/S (Denmark). Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT, 3D-CRT) Internal (LDR, HDR)), Application (Prostate, Breast, Lung), End User (Hospitals) – Global Forecasts to 2026 https://www.marketsandmarkets.com/Market-Reports/radiotherapy-monitoring-devices-market-567.html Patient Positioning System Market by Product (Tables (Surgical Tables, Radiolucent Imaging Tables), Accessories), Application (Surgery, Cancer Therapy, Disease Diagnosis), and End User (Hospitals, Ambulatory Surgery Center) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/patient-positioning-system-market-12586699.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/particle-therapy-market.asp